Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1490979 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL1490978 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL4657294 | 0.84 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL4657292 | 0.84 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL12303043 | 0.82 | MAPT (0.43) | KDM4EALDH1A1 | |
| SCHEMBL923731 | 0.82 | MAPT (0.43) | KDM4EALDH1A1 | |
| SCHEMBL923732 | 0.82 | MAPT (0.43) | KDM4EALDH1A1 | |
| SCHEMBL12697881 | 0.73 | USP2 (0.44) | ALDH1A1 | |
| SCHEMBL153561 | 0.71 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL153560 | 0.71 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| CN-102482283-A | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC | 2012-05-30 | — | — | CN | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | KDM4E 3835/4885ALDH1A1 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.